Previous 10 | Next 10 |
home / stock / mrna / mrna articles
The CNN Money Fear and Greed index showed some easing in overall market sentiment, but the index remained in the "Greed" zone on Thursday...
The stock market witnessed a notable surge today, with the Dow Jones rising 0.43% to 37,248.35 and the S&P 500 gaining 0.26% to 4,719.55. The N...
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's pr...
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected f...
U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Thursday. Shares of Jabil Inc. (NYSE: JBL) rose during Thursday&rs...
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA...
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday. Shares of Pfizer Inc. (NYSE: PFE) shares fell sh...
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and long-term business goals. The compan...
The S&P 500 Index has risen by 19% year-to-date, with three weeks remaining in the year and just a five percentage point gap from the all-time ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...